Jumpstarting U.S. Device Trials? FDA Makes Effort In New Draft Guidelines
This article was originally published in The Gray Sheet
Executive Summary
New FDA guidances aim to strike a balance by allowing firms to begin trials earlier through adaptive study designs, while ensuring that patients are adequately protected.
You may also be interested in...
FDA Abandons Proposal For Interactive, “Pre-Decisional” IDE
The agency finalized a guidance document on investigational device exemption review decisions, dropping a proposal to establish a new, interactive “pre-decisional” IDE process. Industry had been skeptical that the proposed program would improve efficiency of study reviews, and worries that it would require a lot of FDA resources.
FDA Finalizes Guidance On Early-Stage Clinical Trials
FDA released final guidance on granting investigational device exemptions for early feasibility medical device clinical studies October 1. It grants manufacturers additional flexibility to change the clinical protocol in early feasibility trials, which are often conducted as the device’s design is still being finalized.
FDA Finalizes Guidance On Early-Stage Clinical Trials
FDA released final guidance on granting investigational device exemptions for early feasibility medical device clinical studies Oct. 1. It grants manufacturers additional flexibility to change the clinical protocol in early feasibility trials, which are often conducted as the device’s design is still being finalized.